| Medical and Health Sciences | 2021-2025 | 673 | US 228 | 99.85 |
| Environmental Science and Ecology | 2021-2025 | 240 | US 29 | 99.78 |
| Immunology and Allergy | Lifetime | 38 | US 19 | 99.31 |
| Health, Toxicology and Mutagenesis | Lifetime | 336 | US 125 | 98.64 |
| Immunology | Lifetime | 787 | US 402 | 97.46 |
| Dermatology | Lifetime | 641 | US 256 | 94.14 |
| Health, Toxicology and Mutagenesis | 2021-2025 | 13 | US 4 | 99.87 |
| Immunology and Allergy | 2021-2025 | 10 | US 5 | 99.36 |
| Medical Physiology | 2021-2025 | 296 | US 101 | 96.03 |
| Immunology | 2021-2025 | 344 | US 116 | 91.04 |
| Infectious Diseases | 2021-2025 | 394 | US 158 | 92.23 |
| Dermatology | 2021-2025 | 260 | US 92 | 87.71 |
| Pollution | 2021-2025 | 561 | US 35 | 85.23 |
| Food Allergy and Anaphylaxis Research | Lifetime | 34 | US 13 | 99.66 |
| Allergic Rhinitis and Sensitization | Lifetime | 77 | US 25 | 99.56 |
| Asthma and respiratory diseases | Lifetime | 219 | US 85 | 99.40 |
| Climate Change and Health Impacts | Lifetime | 118 | US 46 | 98.96 |
| Air Quality and Health Impacts | Lifetime | 533 | US 203 | 98.72 |
| Eosinophilic Esophagitis | Lifetime | 260 | US 99 | 98.61 |
| IL-33, ST2, and ILC Pathways | Lifetime | 175 | US 79 | 98.22 |
| Dermatology and Skin Diseases | Lifetime | 810 | US 225 | 96.45 |
| Contact Dermatitis and Allergies | Lifetime | 541 | US 133 | 95.84 |
| Drug-Induced Adverse Reactions | Lifetime | 771 | US 235 | 92.02 |
| Climate Change and Health Impacts | 2021-2025 | 9 | US 3 | 99.78 |
| Air Quality and Health Impacts | 2021-2025 | 23 | US 4 | 99.71 |
| Food Allergy and Anaphylaxis Research | 2021-2025 | 13 | US 9 | 99.44 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 40 | US 10 | 99.28 |
| Asthma and respiratory diseases | 2021-2025 | 133 | US 31 | 98.74 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 744 | US 231 | 97.08 |
| COVID-19 Clinical Research Studies | 2021-2025 | 914 | US 211 | 96.30 |
| Pediatric health and respiratory diseases | 2021-2025 | 108 | US 18 | 92.87 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 151 | US 59 | 91.61 |
| Eosinophilic Esophagitis | 2021-2025 | 330 | US 121 | 92.89 |
| Energy and Environment Impacts | 2021-2025 | 514 | US 34 | 91.50 |
| Dermatology and Skin Diseases | 2021-2025 | 972 | US 222 | 87.25 |
| Healthcare cost, quality, practices | 2021-2025 | 444 | US 188 | 81.34 |
| Drug-Induced Adverse Reactions | 2021-2025 | 352 | US 84 | 82.16 |
| Immune responses and vaccinations | 2021-2025 | 263 | US 81 | 78.64 |
| Thermoregulation and physiological responses | 2021-2025 | 574 | US 131 | 79.74 |
| Contact Dermatitis and Allergies | 2021-2025 | 589 | US 130 | 76.66 |
| Transgenic Plants and Applications | 2021-2025 | 348 | US 66 | 71.67 |
| Delphi Technique in Research | 2021-2025 | 653 | US 74 | 71.54 |
| Climate Change Communication and Perception | 2021-2025 | 695 | US 208 | 65.19 |
